 "Vaccine")
Pfizer Inc. said it could seek emergency-use authorization for its Covid-19 vaccine in the US by late November if the shot is shown to be effective in a large late-stage trial.
Safety review dictates the timeline, with the Food and Drug Administration requiring that at least half the people in the study be watched for side effects for two months. That milestone should be achieved in the third week of November, Pfizer Chief Executive Officer Albert Bourla said in an open letter published Friday on the company’s website.
“Let me be clear, assuming positive data, Pfizer will apply for emergency authorization use
